Sivik Global Healthcare LLC Has $4.32 Million Stake in Medtronic PLC $MDT

Sivik Global Healthcare LLC decreased its position in Medtronic PLC (NYSE:MDT) by 25.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 45,000 shares of the medical technology company’s stock after selling 15,000 shares during the period. Medtronic makes up approximately 1.3% of Sivik Global Healthcare LLC’s holdings, making the stock its 19th biggest position. Sivik Global Healthcare LLC’s holdings in Medtronic were worth $4,323,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Barclays PLC increased its stake in shares of Medtronic by 104.6% in the 3rd quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock valued at $650,604,000 after acquiring an additional 3,492,192 shares in the last quarter. Schroder Investment Management Group increased its stake in shares of Medtronic by 78.3% in the 3rd quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company’s stock valued at $717,143,000 after acquiring an additional 3,307,211 shares in the last quarter. Guinness Asset Management LTD bought a new stake in shares of Medtronic in the 3rd quarter valued at $275,556,000. Wellington Management Group LLP increased its stake in shares of Medtronic by 35.3% in the 3rd quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock valued at $970,456,000 after acquiring an additional 2,658,981 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of Medtronic by 2,297.7% in the 4th quarter. SG Americas Securities LLC now owns 2,510,712 shares of the medical technology company’s stock valued at $241,179,000 after acquiring an additional 2,406,000 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Market reports highlight long-term demand growth in segments where Medtronic competes (anesthesia & respiratory devices; lung cancer surgery), supporting structural revenue tailwinds for MDT. Global Anesthesia and Respiratory Devices Market Size/Share Worth USD 100.5 Billion by 2035
• Positive Sentiment: Healthcare market analysis cites rising adoption of minimally invasive and robotic-assisted technologies — a growth area that includes Medtronic’s surgical portfolio. Global Lung Cancer Surgery Market | Rise at 5.9% CAGR
• Positive Sentiment: Several sell‑side firms (Citigroup, Evercore, Argus) cut price targets but maintained Buy/Outperform ratings, indicating confidence in MDT’s long‑term fundamentals despite near‑term modeling changes. Evercore Adjusts Medtronic Price Target to $108
• Neutral Sentiment: Headline market activity lifted NYSE-listed names, including MDT — broader market moves are contributing to today’s modest uptick rather than company‑specific news. Medtronic plc Climbs As NYSE Composite Shows Market Activity
• Neutral Sentiment: Comparative financial write‑ups (OMER vs MDT; MGNX vs MDT) provide investor context but contain no new MDT‑specific catalysts. Omeros and Medtronic Financial Review MacroGenics vs. Medtronic Financial Comparison
• Negative Sentiment: Stifel lowered its price target to $95 and reiterated a Hold, explicitly citing transaction‑related impacts from the MiniMed diabetes IPO / spin‑off as limiting near‑term upside; this is a direct headwind for sentiment. Stifel Cuts MDT Target to $95, Cites MiniMed IPO Effects
• Negative Sentiment: Analyst notes and coverage (TipRanks, Stifel commentary) emphasize that the MiniMed IPO/dilution and the diabetes spin‑off could cap near‑term stock appreciation, reinforcing cautious ratings. Medtronic: MiniMed IPO Dilution and Diabetes Spin-Off Limit Near-Term Upside
• Negative Sentiment: Competitive news: J&J launched an enhanced pulsed‑field ablation (PFA) platform in Europe — a potential competitive pressure in cardiac electrophysiology markets where Medtronic also competes. J&J launches enhanced PFA device in Europe

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on MDT. Wells Fargo & Company initiated coverage on shares of Medtronic in a research note on Friday, January 30th. They issued an “overweight” rating and a $114.00 price objective for the company. JPMorgan Chase & Co. reduced their price objective on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. Mizuho raised Medtronic to a “strong-buy” rating in a research note on Wednesday, February 18th. UBS Group reaffirmed a “neutral” rating and issued a $104.00 price target on shares of Medtronic in a research report on Wednesday, February 4th. Finally, Robert W. Baird dropped their price target on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, Medtronic has an average rating of “Moderate Buy” and an average target price of $109.10.

Medtronic Stock Up 0.1%

Shares of NYSE:MDT opened at $86.40 on Wednesday. The company has a market capitalization of $110.92 billion, a PE ratio of 24.07, a price-to-earnings-growth ratio of 2.24 and a beta of 0.75. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The business has a fifty day moving average price of $93.90 and a two-hundred day moving average price of $96.13. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same quarter in the previous year, the firm posted $1.38 earnings per share. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.3%. Medtronic’s payout ratio is 79.11%.

Insider Transactions at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.26% of the stock is currently owned by company insiders.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).